Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 47Neoplasms 10Prostatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms, Male 5Sarcoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2

Interventions

tremelimumab 1ixabepilone 1durvalumab 1ST 1481 1Paclitaxel 1Fulvestrant 1Docetaxel 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Malignancies × ixabepilone × Clear all
NCT00162136 2020-11-02

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

R-Pharm

Phase 1 Completed
35 enrolled 17 charts

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡